Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
RESEARCH TOOLSreports
Larimar Therapeutics (LRMR) Stock Price & Analysis
316 Followers
LRMR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.18 - $13.68
Previous Close$6.44
Volume144.23K
Average Volume (3M)646.15K
Market Cap
$412.15M
Enterprise Value$329.63M
Total Cash (Recent Filing)$86.79M
Total Debt (Recent Filing)$5.55M
Price to Earnings (P/E)-7.7
Beta0.95
Next Earnings
May 08, 2024EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding63,800,017
10 Day Avg. Volume316,722
30 Day Avg. Volume646,147
Standard Deviation0.26
R-Squared0.04
Alpha-0.00292
Financial Highlights & Ratios
Price to Book (P/B)4.94
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-10.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-8.70
Forecast
1Y Price Target
$22.40Price Target Upside247.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Larimar Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentNomlabofusp showed clinically meaningful increases in frataxin levels in Phase 2, indicating potential for addressing the root cause of Friedreich's ataxia.
Financial HealthLarimar Therapeutics has a substantial cash reserve, extending their operational runway and supporting key milestones.
Regulatory MilestoneFDA is receptive to an accelerated approval based on frataxin levels, with Larimar targeting a BLA submission.
Bears Say
Cost Management4Q23 Operating Expenses were higher than anticipated, indicating potential cost management issues.
Financial PerformanceLarimar reported a net loss during FY 2023, with an increase in R&D and G&A expenses compared to the previous year.
Regulatory ConcernsLess pronounced frataxin increases in buccal vs. skin cells and skepticism on accelerated approval path are potential reasons for the stock weakness.
---
Ownership Overview
50.68% Insiders
4.32% Mutual Funds
6.31% Other Institutional Investors
38.70% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LRMR FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was $2.18 and its highest was $13.68 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is May 08, 2024 which is yesterday.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Larimar Therapeutics, Inc. released its earnings results on Mar 14, 2024. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.248 by -$0.052.
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -$0.24.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 63,800,020 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Larimar Therapeutics, Inc. reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.248. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Among the largest hedge funds holding Larimar Therapeutics, Inc.’s share is Deerfield Management Company, LP. It holds Larimar Therapeutics, Inc.’s shares valued at 77M.
---
Larimar Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.40 (247.83% Upside)
$22.40 (247.83% Upside)
Blogger Sentiment
Bullish
LRMR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 86.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $37.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.47%
12-Months-Change
Fundamentals
Return on Equity
-38.36%
Trailing 12-Months
Asset Growth
-24.10%
Trailing 12-Months
Company Description
Larimar Therapeutics, Inc.
Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.
---
LRMR Stock 12 Month Forecast
Average Price Target
$22.40
▲(247.83% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Voyager Therapeutics
―
Crispr Therapeutics AG
―
Alnylam Pharma
―
Best Analysts Covering LRMR
1 Year
1 Year Success Rate
12/19 ratings generated profit
1 Year Average Return
+29.21%
reiterated a buy rating 2 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +29.21% per trade.
---